Literature DB >> 27997058

Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE).

William Barclay1, Mari L Shinohara1,2.   

Abstract

The aptly named inflammasomes are powerful signaling complexes that sense inflammatory signals under a myriad of conditions, including those from infections and endogenous sources. The inflammasomes promote inflammation by maturation and release of the pro-inflammatory cytokines, IL-1β and IL-18. Several inflammasomes have been identified so far, but this review focuses mainly on the NLRP3 inflammasome. By still ill-defined activation mechanisms, a sensor molecule, NLRP3 (NACHT, LRR and PYD domains-containing protein 3), responds to danger signals and rapidly recruits ASC (apoptosis-associated speck-like protein containing a CARD) and pro-caspase-1 to form a large oligomeric signaling platform-the inflammasome. Involvement of the NLRP3 inflammasome in infections, metabolic disorders, autoinflammation, and autoimmunity, underscores its position as a central player in sensing microbial and damage signals and coordinating pro-inflammatory immune responses. Indeed, evidence in patients with multiple sclerosis (MS) suggests inflammasome activation occurs during disease. Experiments with the mouse model of MS, experimental autoimmune encephalomyelitis (EAE), specifically describe the NLRP3 inflammasome as critical and necessary to disease development. This review discusses recent studies in EAE and MS which describe associations of inflammasome activation with promotion of T cell pathogenicity, infiltration of cells into the central nervous system (CNS) and direct neurodegeneration during EAE and MS.
© 2016 International Society of Neuropathology.

Entities:  

Keywords:  IFNβ; IL-1β; NLRP3; experimental autoimmune encephalomyelitis (EAE); inflammasomes; multiple sclerosis (MS)

Mesh:

Substances:

Year:  2017        PMID: 27997058     DOI: 10.1111/bpa.12477

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  44 in total

Review 1.  Metabolic regulation of inflammasomes in inflammation.

Authors:  Qiuli Yang; Ruichen Liu; Qing Yu; Yujing Bi; Guangwei Liu
Journal:  Immunology       Date:  2019-04-08       Impact factor: 7.397

Review 2.  Inflammasomes and adaptive immune responses.

Authors:  Katherine A Deets; Russell E Vance
Journal:  Nat Immunol       Date:  2021-02-18       Impact factor: 25.606

3.  The NLRP3 inflammasome in progressive multiple sclerosis.

Authors:  Atsushi Kadowaki; Francisco J Quintana
Journal:  Brain       Date:  2020-05-01       Impact factor: 13.501

4.  Deletion of Arginase 2 Ameliorates Retinal Neurodegeneration in a Mouse Model of Multiple Sclerosis.

Authors:  Chithra D Palani; Abdelrahman Y Fouda; Fang Liu; Zhimin Xu; Eslam Mohamed; Shailedra Giri; Sylvia B Smith; Ruth B Caldwell; S Priya Narayanan
Journal:  Mol Neurobiol       Date:  2019-07-06       Impact factor: 5.590

Review 5.  The hygiene hypothesis in autoimmunity: the role of pathogens and commensals.

Authors:  Jean-François Bach
Journal:  Nat Rev Immunol       Date:  2017-10-16       Impact factor: 53.106

Review 6.  Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?

Authors:  Bianca Guglietti; Srisankavi Sivasankar; Sanam Mustafa; Frances Corrigan; Lyndsey E Collins-Praino
Journal:  Mol Neurobiol       Date:  2021-08-25       Impact factor: 5.590

7.  Analysis of NOD-like receptor NLRP1 in multiple sclerosis families.

Authors:  Cecily Q Bernales; Mary Encarnacion; Maria G Criscuoli; Irene M Yee; Anthony L Traboulsee; A Dessa Sadovnick; Carles Vilariño-Güell
Journal:  Immunogenetics       Date:  2017-10-07       Impact factor: 2.846

Review 8.  Alcohol and multiple sclerosis: an immune system-based review.

Authors:  Maryam Fahim; Aryan Rafiee Zadeh; Pouria Shoureshi; Keyvan Ghadimi; Masoumeh Cheshmavar; Neda Sheikhinia; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-04-15

9.  Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?

Authors:  Karen Henriette Pinke; Sofia Fernanda Gonçalves Zorzella-Pezavento; Thais Fernanda de Campos Fraga-Silva; Luiza Ayumi Nishiyama Mimura; Larissa Ragozo Cardoso de Oliveira; Larissa Lumi Watanabe Ishikawa; Ana Angélica Henrique Fernandes; Vanessa Soares Lara; Alexandrina Sartori
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

10.  Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis.

Authors:  Brienne A McKenzie; Manmeet K Mamik; Leina B Saito; Roobina Boghozian; Maria Chiara Monaco; Eugene O Major; Jian-Qiang Lu; William G Branton; Christopher Power
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.